(Z)-7-{(1R,2S)-2-[(E)-(S)-5-(4-bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-5-oxo-3-vinyl-cyclopentyl}-hept-5-enoic acid methyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-7-{(1R,2S)-2-[(E)-(S)-5-(4-bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-5-oxo-3-vinyl-cyclopentyl}-hept-5-enoic acid methyl ester
• 英文别名: methyl (Z)-7-[(1R,2S)-2-[(E,3S)-5-(4-bromo-5-methylthiophen-2-yl)-3-[tert-butyl(dimethyl)silyl]oxypent-1-enyl]-3-ethenyl-5-oxocyclopentyl]hept-5-enoate
• 化学式: C₃₁H₄₇BrO₄SSi
• 分子量: 623.767
• InChiKey: BORROCJCNDPBMY-DOAMVCOKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.0
• 重原子数：
  38
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (Z)-7-{(1R,2S)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-5-oxo-cyclopent-3-enyl}-hept-5-enoic acid methyl ester 、 乙烯基溴化镁 在 碘化亚铜 四氢呋喃 、 氯化铵 、 乙酸乙酯 、 Sodium sulfate-III 、 silica gel 、 ethyl acetate hexanes 作用下， 以 四氢呋喃 为溶剂， 反应 1.92h， 以gave the title ketone (138 mg, 0.22 mmol, 79%)的产率得到(Z)-7-{(1R,2S)-2-[(E)-(S)-5-(4-bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-5-oxo-3-vinyl-cyclopentyl}-hept-5-enoic acid methyl ester
  参考文献：
  名称：

  Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents

  摘要：

  本文披露了一种包含或其药学上可接受的盐或前药的化合物，其具有在此详细描述的基团。本文还披露了包含该化合物或其衍生物、药学上可接受的盐、四氮唑或该结构的化合物或其衍生物的前药的化合物，所述衍生物在此详细描述。本文还披露了治疗疾病或病症的方法，包括青光眼和眼内压升高。还披露了与其相关的制药组合物和制药方法。

  公开号：

  US08168680B2

文献信息

• CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Donde Yariv

  公开号：US20110130439A1

  公开（公告）日：2011-06-02

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

  本文披露了一种化合物，包括具体在此详述的基团或其药物可接受的盐或前药。本文还披露了包括该化合物或其衍生物、药物可接受的盐、四唑或该结构或其衍生物的前药的化合物，所述衍生物在此详述。本文还披露了治疗疾病或症状的方法，包括青光眼和眼内压升高。还披露了相关药物的组成和制造方法。
• Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
  申请人：Donde Yariv

  公开号：US20060035949A1

  公开（公告）日：2006-02-16

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

  本文披露了一种含有所述详细描述的基团的化合物或其药学上可接受的盐或前药。本文还披露了包括其衍生物或药学上可接受的盐、四氮唑或所述结构物的前药的化合物。所述衍生物在此处详细描述。本文还披露了治疗疾病或病况的方法，包括青光眼和眼内压升高。还披露了与此相关的药物制剂的组成和制造方法。